Skip to main content

VolitionRx Limited (VNRX) Stock Forecast

Data as of May 4, 2026

Healthcare · Current price $2.42 (+0.41%)

Consensus Target
Upside
Analysts
14
Rating
Buy(2.14)

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy4
Hold1
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

VNRX vs Sector & Market

MetricVNRXHealthcare AvgLarge Cap Avg
Analyst Rating2.142.242.41
Analyst Count14818
Target Upside+1148.8%+14.9%
P/E Ratio-0.646.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$1M$8M$21M3
2027-12-31$4M$50M$137M3
2028-12-31$11M$82M$228M3
2029-12-31$24M$172M$483M2
2030-12-31$33M$236M$662M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.31$-0.09$0.012
2027-12-31$-0.03$0.12$0.262
2028-12-31$-0.13$0.24$0.813
2029-12-31$-0.07$0.60$2.011
2030-12-31$-0.10$0.81$2.731

Frequently Asked Questions

What is the analyst consensus for VNRX?

The consensus among 14 analysts covering VolitionRx Limited (VNRX) is Buy with an average price target of N/A.

How many analysts cover VNRX?

14 analysts have issued ratings for VolitionRx Limited in the past 12 months.

Is VNRX a buy or sell right now?

Based on 14 analyst ratings, VNRX has a consensus rating of Buy (2.14/5) with a N/A upside to the consensus target of N/A.

What are the earnings estimates for VNRX?

Analysts estimate VNRX will report EPS of $-0.09 for the period ending 2026-12-31, with revenue estimated at $8M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.